Brief: Becton Dickinson's Hpv Assay Receives FDA Approval
21/02/2023 11:56
Feb 21 (Reuters) - Becton Dickinson and Co BDX.N :
* BD ONCLARITY™ HPV ASSAY RECEIVES FDA APPROVAL FOR USE WITH
BOTH
BD SUREPATH™ LIQUID-BASED PAP TEST AND HOLOGIC THINPREP® PAP
TEST
Source text for Eikon: ID:nPn2Yy08ja
Further company coverage: BDX.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Becton Dickinson and Co
See all newsCorrected: BDx secures data center power contract from Indonesia's PLN
China's commerce ministry holds meeting with foreign pharmaceutical firms
Brief: Becton Dickinson Euro Finance S.À R.L Files For Euro-Denominated 600 Million 3.855% Notes Offering Due 2033 - SEC Filing
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
Becton Dickinson raises 2026 profit forecast on drug delivery devices demand (updated)